Inhibition of c-Rel expression in myeloid and lymphoid cells with distearoyl -phosphatidylserine (DSPS) liposomal nanoparticles encapsulating therapeutic siRNA.
Journal
PloS one
ISSN: 1932-6203
Titre abrégé: PLoS One
Pays: United States
ID NLM: 101285081
Informations de publication
Date de publication:
2022
2022
Historique:
received:
06
03
2022
accepted:
14
10
2022
entrez:
15
12
2022
pubmed:
16
12
2022
medline:
20
12
2022
Statut:
epublish
Résumé
c-Rel, a member of the nuclear factor kappa B (NF-κB) family, is preferentially expressed by immune cells and is known to regulate inflammation, autoimmune diseases and cancer. However, there is a lack of therapeutic intervention to specifically inhibit c-Rel in immune cells. Recent success with Pfizer and Moderna mRNA lipid-encapsulated vaccines as well as FDA approved medicines based on siRNA prompted us to test a lipid nanoparticle-based strategy to silence c-Rel in immune cells. Specifically, we encapsulated c-Rel-targeting siRNA into distearoyl-phosphatidylserine (DSPS)-containing nanoparticles. DSPS is a saturated phospholipid that serves as the "eat-me" signal for professional phagocytes such as macrophages and neutrophils of the immune system. We demonstrated here that incorporation of DSPS in liposome nanoparticles (LNP) improved their uptake by immune cells. LNP containing high concentrations of DSPS were highly effective to transfect not only macrophages and neutrophils, but also lymphocytes, with limited toxicity to cells. However, LNP containing low concentrations of DSPS were more effective to transfect myeloid cells than lymphoid cells. Importantly, DSPS-LNP loaded with a c-Rel siRNA were highly effective to inhibit c-Rel expression in several professional phagocytes tested, which lasted for several days. Taken together, our results suggest that DSPS-LNP armed with c-Rel siRNA could be exploited to target immune cells to limit the development of inflammatory diseases or cancer caused by c-Rel upregulation. In addition, this newly developed DSPS-LNP system may be further tested to encapsulate and deliver other small molecule drugs to immune cells, especially macrophages, neutrophils, and lymphocytes for the treatment of diseases.
Identifiants
pubmed: 36520934
doi: 10.1371/journal.pone.0276905
pii: PONE-D-22-06731
pmc: PMC9754606
doi:
Substances chimiques
RNA, Small Interfering
0
Liposomes
0
Phosphatidylserines
0
Types de publication
Journal Article
Research Support, N.I.H., Extramural
Langues
eng
Sous-ensembles de citation
IM
Pagination
e0276905Subventions
Organisme : NIAID NIH HHS
ID : R01 AI099216
Pays : United States
Organisme : NIAID NIH HHS
ID : R01 AI121166
Pays : United States
Informations de copyright
Copyright: © 2022 Bressy et al. This is an open access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Déclaration de conflit d'intérêts
The authors have declared that no competing interests exist.
Références
ACS Nano. 2021 Nov 23;15(11):16982-17015
pubmed: 34181394
Oncogene. 2016 Jun 30;35(26):3476-84
pubmed: 26522720
J Biomed Nanotechnol. 2014 Jun;10(6):982-92
pubmed: 24749393
N Engl J Med. 2020 Apr 16;382(16):1507-1519
pubmed: 32187462
PLoS One. 2010 Mar 02;5(3):e9488
pubmed: 20209146
J Immunol. 2011 Nov 1;187(9):4483-91
pubmed: 21940679
Gut. 2009 Aug;58(8):1078-83
pubmed: 19240061
Vet Immunol Immunopathol. 2014 Apr 15;158(3-4):224-32
pubmed: 24598124
Nat Rev Drug Discov. 2021 Feb;20(2):101-124
pubmed: 33277608
Expert Rev Vaccines. 2020 Mar;19(3):279-292
pubmed: 32228108
Orphanet J Rare Dis. 2013 Feb 20;8:31
pubmed: 23425518
Front Oncol. 2021 Apr 20;11:638897
pubmed: 33959502
Front Immunol. 2012 Jul 04;3:174
pubmed: 22783254
Oncogene. 1999 Nov 22;18(49):6938-47
pubmed: 10602468
Biotechnol J. 2011 Sep;6(9):1130-46
pubmed: 21744502
PLoS One. 2012;7(8):e44197
pubmed: 22952927
Lancet Microbe. 2022 Mar;3(3):e193-e202
pubmed: 35098177
J Exp Med. 2011 Oct 24;208(11):2321-33
pubmed: 22006976
Korean J Anesthesiol. 2010 Dec;59(6):403-10
pubmed: 21253378
Genome Biol Evol. 2022 Jan 4;14(1):
pubmed: 34999783
Eur J Immunol. 2008 Sep;38(9):2616-25
pubmed: 18792414
iScience. 2020 Mar 27;23(3):100876
pubmed: 32062419
Oncotarget. 2015 Sep 15;6(27):23157-80
pubmed: 26324762
Nano Lett. 2013 Jun 12;13(6):2448-57
pubmed: 23650871
Biomater Res. 2021 Dec 20;25(1):44
pubmed: 34930494
Int Immunopharmacol. 2018 Mar;56:9-17
pubmed: 29324391
Genes Cancer. 2011 Jul;2(7):695-711
pubmed: 22207895
Bioact Mater. 2020 Dec 26;6(7):1973-1987
pubmed: 33426371
Oncol Rep. 2012 Apr;27(4):1003-10
pubmed: 22200969
Nano Lett. 2016 Sep 14;16(9):5503-13
pubmed: 27525587
Front Chem. 2020 Dec 21;8:597806
pubmed: 33409265
Cell. 2017 Sep 7;170(6):1096-1108.e13
pubmed: 28886380
Amyloid. 2016 Jun;23(2):109-18
pubmed: 27033334
Pharmaceutics. 2019 Jul 24;11(8):
pubmed: 31344836
Science. 2008 Feb 1;319(5863):627-30
pubmed: 18239128
Sci Adv. 2020 Mar 25;6(13):eaay1601
pubmed: 32232146
Sci Rep. 2018 May 21;8(1):7952
pubmed: 29785035
Sci Rep. 2016 Jul 14;6:29891
pubmed: 27412723
Nat Immunol. 2011 Jul 19;12(8):683-5
pubmed: 21772275
Biotechniques. 2022 May;72(5):219-224
pubmed: 35369729
Eur J Immunol. 2021 Aug;51(8):2006-2026
pubmed: 33960413
Clin Microbiol Infect. 2022 Jan;28(1):130-134
pubmed: 34592420
Immunol Cell Biol. 2017 Aug;95(7):593-600
pubmed: 28202908
Lancet Infect Dis. 2022 Mar;22(3):329-340
pubmed: 34826381
J Clin Invest. 2002 Sep;110(6):843-50
pubmed: 12235116
Front Physiol. 2018 Feb 20;9:113
pubmed: 29515456
Clin Immunol. 2016 Apr;165:47-54
pubmed: 26993753
Pharmaceutics. 2022 Apr 08;14(4):
pubmed: 35456655
Mol Ther. 2021 Nov 3;29(11):3293-3304
pubmed: 34091054
Curr Top Microbiol Immunol. 2011;349:245-63
pubmed: 21113699
J Crohns Colitis. 2022 Feb 23;16(2):286-300
pubmed: 34286840
Nat Commun. 2017 Nov 23;8(1):1747
pubmed: 29170511
Cell Biol Int Rep (2010). 2011;18(1):e00010
pubmed: 23119146
Int Immunol. 2014 Jan;26(1):35-46
pubmed: 24065781
Proc Natl Acad Sci U S A. 2000 Nov 7;97(23):12705-10
pubmed: 11058167
Cancer Res. 2016 Jan 15;76(2):377-89
pubmed: 26744524
N Engl J Med. 2020 Jun 11;382(24):2289-2301
pubmed: 32521132
J Nanobiotechnology. 2017 Nov 17;15(1):83
pubmed: 29149896
PLoS One. 2009;4(4):e5028
pubmed: 19347041
Pharmaceuticals (Basel). 2021 Nov 17;14(11):
pubmed: 34832955
Biomaterials. 2014 Jan;35(1):590-600
pubmed: 24125775
Innovation (Camb). 2021 Oct 14;2(4):100174
pubmed: 34766099
Pharmaceutics. 2020 Nov 04;12(11):
pubmed: 33158166
Sci Adv. 2020 Jan 15;6(3):eaax5032
pubmed: 31998834
Nat Med. 2021 Nov;27(11):2025-2031
pubmed: 34526698
J Hematop. 2009 Mar;2(1):20-6
pubmed: 19669219
PLoS One. 2009 Sep 17;4(9):e7089
pubmed: 19759907
Blood. 2007 Apr 1;109(7):3060-8
pubmed: 17138822
Oncogene. 2008 Dec 4;27(53):6770-81
pubmed: 18695674
N Engl J Med. 2021 Feb 4;384(5):403-416
pubmed: 33378609
Nat Cancer. 2020 May;1(5):507-517
pubmed: 33458695
Nanomaterials (Basel). 2021 Jun 30;11(7):
pubmed: 34209111
Nat Rev Neurol. 2018 Oct;14(10):570
pubmed: 30158559
RNA Biol. 2020 Jun;17(6):755-764
pubmed: 32050839
N Engl J Med. 2021 Sep 16;385(12):1078-1090
pubmed: 34432976
Int J Mol Sci. 2018 Sep 23;19(10):
pubmed: 30249040
Cancer Gene Ther. 2003 Feb;10(2):125-33
pubmed: 12536201
Nat Commun. 2019 Aug 15;10(1):3686
pubmed: 31417080
Int Immunol. 1999 Mar;11(3):361-71
pubmed: 10221648
J Immunol Res. 2018 Jun 11;2018:1467538
pubmed: 29992170
Clin Dev Immunol. 2012;2012:239368
pubmed: 22481964
Exp Mol Med. 2017 May 12;49(5):e331
pubmed: 28496201
Nucleic Acids Res. 2006 Jan 12;34(1):322-33
pubmed: 16410612
Nat Genet. 2009 Jul;41(7):820-3
pubmed: 19503088
Mol Ther. 2017 Jul 5;25(7):1491-1500
pubmed: 28392163
Sci Rep. 2016 Nov 28;6:37849
pubmed: 27892533
Front Immunol. 2018 Feb 05;9:155
pubmed: 29459867
J Invest Dermatol. 2016 Jun;136(6):1090-1096
pubmed: 27032306
Methods Mol Biol. 2014;1121:47-54
pubmed: 24510810
N Engl J Med. 2021 Apr 1;384(13):1216-1226
pubmed: 33789010
N Engl J Med. 2018 Jul 5;379(1):11-21
pubmed: 29972753
Nat Genet. 2010 Dec;42(12):1126-1130
pubmed: 21037568
Biochem J. 1980 Feb 15;186(2):591-8
pubmed: 7378067
Technol Cancer Res Treat. 2007 Aug;6(4):255-60
pubmed: 17668932
Bioact Mater. 2021 Jun 04;7:167-180
pubmed: 34466725
Front Pharmacol. 2019 Mar 12;10:220
pubmed: 30914953
ACS Nano. 2019 Feb 26;13(2):1116-1126
pubmed: 30609354
Nanomedicine (Lond). 2008 Oct;3(5):703-17
pubmed: 18817471
J Clin Invest. 2002 Sep;110(6):741-2
pubmed: 12235102
Pharmaceutics. 2021 Nov 04;13(11):
pubmed: 34834282
Int J Nanomedicine. 2016 Oct 12;11:5287-5310
pubmed: 27789943
HFSP J. 2007 Nov;1(4):225-9
pubmed: 19404423
J Clin Invest. 2021 Sep 1;131(17):
pubmed: 34623332
Theranostics. 2019 Sep 21;9(23):6867-6884
pubmed: 31660074
J Nanobiotechnology. 2021 May 29;19(1):160
pubmed: 34051801
Bioeng Transl Med. 2021 Aug 13;6(3):e10246
pubmed: 34514159
J Drug Deliv. 2011;2011:727241
pubmed: 21512579
Front Immunol. 2021 Oct 11;12:714170
pubmed: 34707602
Sci Adv. 2022 Feb 18;8(7):eabm1418
pubmed: 35171673
N Engl J Med. 2020 Dec 31;383(27):2603-2615
pubmed: 33301246
Immunol Cell Biol. 2014 Sep;92(8):699-708
pubmed: 24890643
Bioelectrochemistry. 2021 Oct;141:107871
pubmed: 34147013
Theranostics. 2022 Jan 1;12(1):434-458
pubmed: 34987658
Blood. 2005 Aug 15;106(4):1392-9
pubmed: 15870177
Br J Cancer. 2016 Jan 12;114(1):1-6
pubmed: 26757421